Rifaximin

RIFAVIB 200

COMPOSITION
Rifaximin200MG
SPECIFICATION
FORMTABLET
PACKING 10×10
PACKING TYPEALU ALU
MRP1450

DESCRIPTION

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller’s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

SIDE EFFECTS

LD50 > 2 g/kg (orally, in rats)

INDICATION

Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller’s diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.